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Supersaturated lipid-based drug delivery systems – exploring impact of 
lipid composition type and drug properties on supersaturability and 
physical stability 
Objective 
The objective of the current study was to systematically investigate the impact of lipid 
composition on the ability to design supersaturated lipid-based drug delivery systems 
(sLBDDS) using three model drugs with different physico-chemical properties.  
Significance 
This study expands the list of investigated sLBDDS by using alternative vehicle 
compositions relative to current literature. 
Methods & Results 
Drug supersaturation was thermally-induced based on previously reported methods and 
was successfully achieved for celecoxib and cinnarizine. For the novel drug, JNJ-2A, a 
lower supersaturation potential was observed for the tested LBDDS. For celecoxib and 
cinnarizine, crystalline precipitate was observed for some sLBDDS upon storage at 
25°C/65%RH, particularly for medium chain sLBDDS (celecoxib) and long chain 
sLBDDS (cinnarizine). The greater risk of precipitation observed for celecoxib and 
cinnarizine, particularly at higher apparent degree of supersaturation (aDS) may be 
related to their higher crystallization tendency as determined by differential scanning 
calorimetry.  
Conclusions 
In conclusion, the potential for supersaturation in LBDDS, and the risk of precipitation, 
was found to be highly drug dependent. The apparent degree of supersaturation was 
considered a major factor impacting the ability to maintain drug supersaturation upon 
storage.  
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Poorly water-soluble drug (PWSD) candidates typically exhibit biopharmaceutical challenges 
when formulated as conventional oral dosage forms, leading to erratic or incomplete 
absorption, low bioavailability, high pharmacokinetic variability and food dependent uptake 
[1-3]. With the increasing trend of PWSD emerging from drug discovery programmes [4], 
there is a need to develop novel bio-enabling formulation technologies to address these 
biopharmaceutical limitations [5,6]. Several bio-enabling approaches based on physical 
modifications of drugs have been investigated and include (1) particle size reduction 
(micronization or nanonization), (2) modification of crystal form (co-crystals, polymorphs), 
(3) complexation/solubilisation (inclusion in cyclodextrins or lipid vehicles) or (4) drug 
dispersion in carriers (solid dispersions, solid solutions or eutectic mixtures) [7-9]. 
As a bio-enabling strategy, lipid-based drug delivery systems (LBDDS) offer the 
advantage to present the PWSD pre-solubilised to gastro-intestinal (GI) tract [4,8,9]. LBDDS 
may be formulated with a wide range of lipid excipients, generally including either 
triglycerides, partially digested triglycerides (i.e. mono- and di-glycerides), surfactants or co-
solvents. While various classification schemes have attempted to guide industry on the choice 
of excipient type, the final choice of excipient is highly influenced by the drug type, as well 
empirically driven, based on in-house experience and prior regulatory acceptability [2]. Lipid 
excipients are predominantly obtained from natural sources (i.e. vegetable oils) and their 
function in LBDDS is not only to solubilize and improve the dissolution of PWSDs, but may 
also serve to reduce food-dependent drug absorption and enhance bioavailability by 
stimulation of lymphatic transport [9]. While there are numerous examples of commercially 
successful LBDDS [9-11], a key limitation for more widespread application of LBDDS is that 
the maximum dose loading of drug within the LBDDS is limited by the inherent solubility of 
the drug in the lipid vehicle. This is particularly the case for PWSDs displaying both solid-












medium lipophilicity), where the dose exceeds the drug equilibrium solubility in lipid 
excipients [4]. Formulation strategies to improve maximum dose loading in LBDDS, such as 
the use of co-solvents, are therefore commonly explored [12]. More recently, the potential to 
generate supersaturated drug solutions in LBDDS, i.e. supersaturated LBDDS (sLBDDS), 
have been reported as an approach to enhance drug dose loading in lipid vehicles [13-16].  
From a drug development perspective, formulation scientists are increasingly 
operating within reduced timelines with an emphasis on accelerating development for 
breakthrough therapies [17-19]. For PWSDs this is particularly challenging given that the 
optimal choice of bio-enabling formulation strategy is unclear at early stage preclinical 
development. In addition, for preclinical pharmaco- and toxico-kinetics evaluation there is a 
need to increase doses to up to 30 to 100 times greater (mg/kg) than might be envisaged with 
a clinically relevant dose and formulation in order to demonstrate dose limiting toxicity 
endpoints [12,17,19-21]. A simplified drug development process generally relies on obtaining 
dose proportionality in exposure, thus ensuring a predictable response [21]. Selection of 
formulations for early pharmaco- and toxico-kinetics studies is based on high throughput 
screening of drug solubility in different solvents, surfactants and lipid excipients and aims at 
finding suitable vehicles to maintain the drug in solution to allow oral dosing in preclinical 
animal models [18]. Generally, easily dose scalable formulations are preferred in preclinical 
studies and typically comprise of solutions and suspensions for both rodent and non-rodent 
species [18,20,21]. 
 sLBDDS offer an advantage in terms of the ability to administer highly concentrated 
solutions of the drug. In contrast, using conventional LBDDS, particularly where drug 
solubility in the vehicle is low, dosing in toxicity studies may become limited by the large 
quantities of excipient often required to afford the higher exposure. sLBDDS can be  
manufactured without recourse to advanced processing approaches (e.g. salt or co-crystal 












promote drug precipitation upon dispersion in the aqueous GI media [18,20,21]. Furthermore, 
when a safe dose range is found in preclinical studies, first-in-human (FIH) clinical studies 
are commonly started typically using similar ‘simple’ formulations (i.e. solution or 
suspension) as used in preclinical studies [20,21]. Supersaturated lipid-based drug delivery 
systems are therefore highly suited to streamline the formulation process in early stage drug 
development, allowing ease of administration as simple lipid solutions in rodent and non-
rodent models, which can be readily scaled to clinical formulation as lipid filled capsules. 
To date, supersaturated drug delivery systems have most commonly been investigated 
for topical and transdermal administration with the advantage of increasing drug loading of 
drugs that otherwise may exhibit limited solubility in lipid vehicles [22,23]. More recently, 
sLBDDS, and specifically self-nano-emulsifying drug delivery systems (i.e. super-SNEDDS) 
have been shown to enhance oral absorption of PWSDs, for drugs such as halofantrine 
[14,15], simvastatin [13], fenofibrate [24] and R3040 [25] in dogs and mini-pigs 
pharmacokinetic studies. However, in these studies a relatively similar composition of 
SNEDDS in terms of lipid, surfactant and co-solvent was employed (e.g. lipid:surfactant:co-
solvent = 55:35:10). The most commonly employed method to produce oral sLBDDS 
involves mixing the drug (at a dose exceeding drug equilibrium solubility in the lipid vehicle) 
with the lipid excipients, heating for a defined period of time (e.g. to 50-60°C) followed by 
cooling to ambient temperature [13-15].  
While sLBDDS have gained biopharmaceutical focus due to their ability to provide 
good in vivo performance, there is a lack of studies exploring formulation design of sLBDDS. 
In particular, no study has, to the best of our knowledge, been reported on the influence of the 
lipid composition on the ability to supersaturate and capability to maintain supersaturation in 
sLBDDS during storage. The overall aim of this study was, therefore, to evaluate the 
influence of formulation complexity and lipid composition type on the ability to design 












ability to maintain supersaturation upon short-term storage. The three model drugs selected 
were a weak acid (celecoxib), a weak base (cinnarizine) and a neutral drug (JNJ-2A), with a 
clogP between 4.3 and 5.7 and different solid-state characteristics.  
2. Materials and methods 
2.1. Chemicals and materials 
Celecoxib was purchased from Astatech Inc. (Bristol, PA, USA), cinnarizine and JNJ-2A 
were obtained from Janssen Pharmaceutica (Beerse, Belgium). Sesame oil (long chain 
triglycerides, LCT) was purchased from Croda (Snaith, United Kingdom), Capmul MCM C8 
(medium chain mixed mono-/di-glycerides, MCM) was kindly donated by Abitec (Columbus, 
OH, USA). Maisine CC (long chain mono-/di-glycerides, LCM), Labrafac Lipophile WL1349 
(medium chain triglycerides, MCT) and Labrasol ALF (hydrophilic surfactant, S) were a kind 
gift from Gattefossé (Lyon, France). All other chemicals and solvents were of analytical or 
HPLC grade and were purchased from WVR (Belgium). 
2.2. Design of prototype lipid-based drug delivery systems 
Composition of the different excipients used in this study is listed in (Supporting information 
Table S 1, [26]) and the components of the prototype lipid-based drug delivery systems are 
shown in Table 1. The mixtures contained either a single lipid component and surfactant 
(LCM+S, MCM+S), two lipid components (mono-di-glycerides blends and triglycerides) with 
same fatty acid length and surfactant (LCM+LCT+S, MCM+MCT+S) or were mixtures of 
two lipid components (mono-di-glycerides blends and tri-glycerides) with different fatty acid 
length and surfactant (LCM+MCT+S, MCM+LCT+S). Excipients for the LBDDS were 
mixed gently for 10 s at ambient temperature until a homogenous solution was obtained. 
These drug-free LBDDS were kept at ambient temperature, 37°C and 60°C for 24 h to mimic 












at ambient temperature and homogeneity or excipient separation was investigated for up to 28 
days at 25°C/65% RH. 
2.3. Crystallization tendency by Differential Scanning Calorimetry 
The crystallization tendency of the three drugs from the undercooled melt state was evaluated 
using differential scanning calorimetry (DSC). Enthalpy of fusion (ΔHfus), melting peak 
temperature (Tm), crystallization peak temperature during cooling (Tcryst,cool), onset and 
midpoint glass transition temperatures (Tg,onset, Tg,mid), and crystallization peak upon heating 
(Tcryst,heat) of the samples were determined in triplicate using a TA Q2000 DSC equipped with 
a refrigerated cooling accessory (TA Instruments, New Castle, DE). From the obtained data, 
entropy of fusion (ΔSfus) and Tm/Tg ratio were determined (both using the Kelvin scale). The 
instrument was calibrated for temperature using adamantane, octadecane, lead, and indium. 
The enthalpic response was calibrated using indium. Nitrogen, 50 mL/min, served as the 
purge gas. For the crystallization screening experiments, samples were prepared in sealed 
pans, heated at 10°C/min to 178°C (celecoxib), 167°C (JNJ-2A) and 123°C (cinnarizine), 
held isothermally for 3 min, cooled to -75°C (10°C/min) and reheated at a rate of 10°C/min to 
the temperature mentioned above. The sample weights for each repeat were between 2-3 mg. 
2.4. Equilibrium drug solubility in lipid-based drug delivery systems 
The physico-chemical properties of the three model drugs used in this study are shown in 
Table 2. All three drugs belong to class II in the Biopharmaceutics Classification System 
(BCS) having good intestinal permeability, but poor water solubility. 
Solubility of the drugs (i.e. celecoxib, cinnarizine and JNJ-2A) in the prototype 
LBDDS was determined by the shake-flask method. In short, an excess amount of drug was 
added to 1 mL of each blank LBDDS in vials containing a magnetic stirrer. Formed 












same experimental design was first pre-tested for the three drugs at 24, 48 and 72 h to 
determine if saturation solubility may be reached within 24 h. Aliquots of the mixtures were 
centrifuged at 17500 rpm for 30 min using an Eppendorf centrifuge 5430R (Eppendorf, 
Hamburg, Germany) at ambient temperature, 37°C and 40°C. The drug concentration in the 
supernatants was determined using an Acquity Ultra Performance Liquid Chromatography 
(UPLC™) H-class system (Waters, Milford, USA) consisting of a binary solvent manager, a 
sample manager and a photodiode array (PDA) detector. The output signal was monitored and 
processed using the Empower
®
 software version 3.0. A reversed-phase Waters Acquity BEH 
C18, 50 mm × 2.1 mm; 1.7 μm column (Waters, Milford, USA) was used for the 
chromatographic analysis with a mobile phase containing a gradient mixture of solvents A 
(0.1% trifluoracetic acid in water) and B (100% acetonitrile – ACN) in the following A/B 
proportions: 60/40 for celecoxib and 70/30 for cinnarizine and JNJ-2A. The flow rate of the 
mobile phase was 0.60 mL/min for celecoxib and cinnarizine and 0.75 mL/min for JNJ-2A 
and the injection volume was 2 μL. The column temperature was maintained at 55°C and the 
wavelength was monitored at 251 nm (celecoxib), 253 nm (cinnarizine) and 280 nm (JNJ-
2A). The calibration curves for the three drugs were confirmed linear between 5 – 100 µg/mL 
and samples were diluted accordingly. The solubility experiment was performed in triplicate.  
2.5. Formulation of supersaturated LBDDS 
The eight LBDDS were loaded with either celecoxib, cinnarizine or JNJ-2A at two elevated 
temperatures (37 and 60°C) with amounts equal to 85% of the equilibrium solubility 
determined at 37°C to prepare for an upcoming in vivo study and equal to 100% of 
equilibrium solubility at 60°C to induce more stress to the LBDDS. The required mass of 
drug was weighed into clean screw-top glass vials and blank LBDDS were added up to the 
target mass loading. Vials were sealed, mixed and incubated at 37°C and 60°C for 24 h and 












sLBDDS was confirmed using the reversed phase UPLC methods described above for all 
three drugs.  
2.5.1. Apparent degree of supersaturation 
The apparent degree of supersaturation (aDS) was determined as the ratio of the concentration 
of the solubilized and molecularly dispersed drug in the supersaturated solution and the 
concentration in the saturated solution as previously reported by Blaabjerg et al. [27]. In this 
study, aDS was calculated according to equation (1) for the LBDDS loaded with drug at 37 
and 60°C.   
aDS = Csupersaturation /Sequilibrium                                                               (1) 
where Csupersaturation is the concentration of the drug determined after heating the LBDDS (at 37 
or 60°C for 24 h) followed by cooling to ambient temperature and Sequilibrium is the equilibrium 
solubility at ambient temperature (as described in section 2.4). 
2.6. Physical stability evaluation of supersaturated lipid systems 
The physical stability of the LBDDS with different apparent degree of supersaturation was 
evaluated during storage at 25°C/65%RH for up to 28 days. Visual and analytical assessments 
at pre-defined timepoints were performed, immediately after drug loading (day 0) and after 1, 
4, 7, 14 and 28 days. The samples were kept in plastic Eppendorf tubes for the duration of the 
stability evaluation.  
2.6.1. Polarized Light Microscopy analysis 
When formulations were noted to contain visible particles, they were microscopically 
analysed with a polarized light microscope (Nikon Eclipse CFI60, 4x) to detect changes in 











of the starting drug material.  
2.6.2. X-ray Powder Diffraction 
Precipitate formed at the bottom of the test tubes was transferred onto zero background 
holders and analysed with X-ray powder diffraction (XRPD) from 3° to 50º 2θ. The analysis 
was carried out on a PANalytical (Philips, Amsterdam, The Netherlands) X’PertPRO MPD 
diffractometer, equipped with a Cu LFF X-ray tube. Diffractograms were compared to the 
ones corresponding to the starting drug material. 
2.7. Data Analysis 
GraphPad Prism Version 7.0 (GraphPad Software, San Diego, CA, USA) was used for all 
graphs. 
3. Results 
3.1. Solid-state characterization of model drugs  
The crystalline characteristics of the three model drugs used in this study were confirmed by 
their respective XRD diffractograms (Supporting information, Figure S 1). In addition, pure 
drug was characterized microscopically under cross-polarized light to determine the shape of 
the crystalline material (Supporting information, Figure S 2). Differential scanning 
calorimetry was performed in the heat-cool-heat mode to investigate the effect of thermal 
treatment on the solid-state and the crystallization tendency of the three drugs. This analysis 
of undercooled drug melt provided information on glass forming ability (GFA) [28], which 
may be an early indicator of supersaturation propensity and hence the ability to generate 
sLBDDS .  
The first heating cycle confirmed the melting point of the three drugs (Tm) (Table 3). 












generating amorphous drug substance, i.e. to a macroscopic solid phase with no crystalline 
structure. Celecoxib crystallized during the cooling phase at a Tcryst,cool of 138°C. No 
crystallization events were observed for the two other drugs. In the re-heating cycle, a glass 
transition (Tg,mid) of 8.5 °C was observed for cinnarizine and 91.2°C for JNJ-2A confirming 
formation of the amorphous material. On further heating, celecoxib and cinnarizine displayed 
endothermic peaks, while no endothermic or exothermic peaks were observed for JNJ-2A 
showing that the drug did not tend to recrystallize, and therefore indicative of the formation of 
an amorphous state. The entropy of fusion (ΔSfus) and Tm/Tg ratio were used as indicators of 
crystallization tendency of the three drugs as illustrated previously by Baird and co-workers 
[28] and Fridgeirsdottir and co-workers [29]. JNJ-2A had a lower Tm/Tg ratio than the other 
model drugs suggesting lower crystallization tendency, which was also reflected in the lower 
value of the entropy of fusion. The experimentally determined values were for JNJ-2A were 
similar to internal J&J data and similarly data for cinnarizine and celecoxib (Supporting 
information, Table S 2) were in good agreement regarding enthalpy of fusion, entropy of 
fusion, and melting temperature [28].  
3.2. Macroscopic and microscopic assessment of drug-free and drug-loaded 
sLBDDS  
All selected lipid excipients displayed good miscibility at the selected ratio (i.e. 
lipid:surfactant = 4:1). In order to assess the suitability of the chosen LBDDS, a macroscopic 
and microscopic assessment was conducted in both drug-free and drug-loaded systems stored 
over 28 days at 25°C/65%RH. All drug-free LBDDS were found to be stable, with no phase 
separation or layering observed. Drug-free LBDDS did not display any traces of material 
resembling the three drugs when analysed microscopically under polarized light (data not 












Macroscopic evaluation of drug-loaded sLBDDS revealed clear and optically 
transparent solutions after 24h stirring at either 37 or 60°C with the exception of three 
LBDDS containing JNJ-2A (i.e. LCM+LCT+S, LCM+MCT+S and MCM+LCT+S) which 
displayed phase separation (Supporting information, Figure S 4). Due to this instability, it was 
methodologically challenging to determine accurate drug concentration for these three mixed 
excipient systems. Further characterisation studies on these three unstable systems with JNJ-
2A were therefore not warranted and thus not continued.  
3.3. Equilibrium drug solubility in LBDDS at ambient temperature 
The equilibrium solubility of the three investigated drugs at ambient temperature in the tested 
LBDDS is shown in Figure 1.  
Similar to previously reported studies, drug solubility of all three drugs was higher in 
MC compared to LC lipid vehicles [30]. Drug solubility was increased by inclusion of a 
surfactant in the LBDDS. For celecoxib, increases of between 4.5 – 6.3-fold were observed in 
the LCM lipid systems containing surfactant (LCM+S, LCM+LCT+S, LCM+MCT+S) 
compared to the surfactant-free LCM system, whereas in the MCM lipid systems (MCM+S, 
MCM+MCT+S, MCM+LCT+S) the increases were lower (1.6 – 2.0-fold) compared to the 
MCM system. In contrast, for cinnarizine, the drug solubility across the eight classes of 
LBDDS were broadly similar, suggesting a relatively low impact of formulation complexity 
on dose loading for this drug. A high increase in solubility (4.4-fold) was observed when a 
hydrophilic surfactant was added to the LCM system for JNJ-2A, whereas the drug solubility 
in MCM systems was similar across the stable LBDDS independent of surfactant inclusion. In 
general, a similar rank order of solubilisation capacity across the various LBDDS was similar 
for the three drugs. For celecoxib the following rank order of mean solubility was observed: 
MCM+S > MCM+MCT+S > LCM+MCT+S > MCM+LCT+S > LCM+S > LCM+LCT+S > 












MCM+LCT+S > LCM+S = LCM > LCM+LCT+S and for JNJ-2A: MCM+S > MCM > 
MCM+MCT+S > LCM+S > LCM. All three rank orders confirm a higher solubilisation 
capacity of LBDDS based on MC mono-/di-glycerides and a poor solubilisation capacity of 
the single LC lipid component (i.e. LCM). 
3.4. Influence of lipid composition type on drug solubility in LBDDS at elevated 
temperature 
The solubility of celecoxib, cinnarizine and JNJ-2A in LBDDS on heating at 37 and 60°C, 
was determined in order to evaluate the influence of lipid composition type on drug solubility 
in LBDDS at elevated temperatures (Table 4).  
For celecoxib, on heating to 37°C solubility in the LBDDS increased between 16.4 
and 39.6% across the LBDDS, relative to solubility at ambient temperature. Similar to 
solubility trends at ambient temperature, the lowest solubility was observed in the LCM 
system (18.6 ± 0.3 mg/mL) and the highest solubility was obtained in MCM+S (138.5 ± 16.5 
mg/mL). Solubility of cinnarizine at 37°C was similar across the eight tested LBDDS with 
increases of 27.5 to 88.9% relative to ambient temperature solubility and ranging from the 
lowest of 37.3 ± 1.2 mg/mL in LCM+LCT+S to the highest solubilized amount of 55.3 ± 2.5 
mg/mL in the LCM system. In the case of JNJ-2A increases between 9.3 and 52.9% were 
observed compared to ambient temperature solubility, with the LCM system also showing the 
lowest solvent capacity for (55.3 ± 0.9 mg/mL) and the highest observed solubility observed 
for MCM+S (461.4 ± 11.9 mg/mL).  
Solubility determinations at 60°C indicated that dose loading of celecoxib was 
increased by 71.8 to 172.8% in the tested LBDDS compared to ambient temperature solubility 
with the lowest solubilized dose in LCM (36.2 ± 2.8 mg/mL) and the highest in MCM+S 
(258.5 ± 51.2 mg/mL). The dose loading of cinnarizine increased between 55.0 and 196.0% in 












in LCM+LCT+S (42.2 ± 0.3 mg/mL) and the highest in the corresponding MC systems, i.e. 
MCM+MCT+S (89.9 ± 8.7 mg/mL). For JNJ-2A, at 60°C, the solubilisation capacity of the 
tested LBDDS increased between 3.6 and 87.7% with the lowest solubilized dose observed 
for LCM (76.5 ± 2.9 mg/mL) and the highest for MCM+MCT+S (507.1 ± 28.4 mg/mL). 
Interestingly, in the case of MCM and MCM+S systems the solubility at 60°C was 
quantitatively lower than the solubility at 37°C, suggesting that no further gains in dose 
loading could be achieved at the higher temperature. 
To get a better understanding of the solubility dependence on temperature in different 
LBDDS, the logarithmic drug solubility (expressed as logS) was plotted as a function of the 
tested temperature (Figure 2). A linear relationship was observed between celecoxib solubility 
with temperature increase for tested LBDDS and similarly in the case of cinnarizine, logS 
increased linearly with temperature in seven of the tested LBDDS, with the exception of 
LCM+LCT+S. For JNJ-2A, three systems, i.e. LCM, LCM+S, MCM+MCT+S, from the five 
tested, showed a linear dependence of LogS with increasing temperature, whereas for two 
systems (i.e. MCM, MCM+S), solubility decreased on increasing temperature from 37°C to 
60°C.  
3.5. Physical stability of supersaturated LBDDS 
3.5.1. Celecoxib sLBDDS 
Results for celecoxib are shown in Table 5 together with apparent degree of supersaturation. 
Over the 28-day period, at 25°C/65%RH, celecoxib sLBDDS formulated at 37°C were 
physically stable with no macroscopic changes in homogeneity, as concluded after 
microscopic and analytical evaluation (data not shown).  
When formulating the sLBDDS by heating to 60°C and storage at 25°C/65%RH, 












formulated at 37°C; however, the physical stability of these celecoxib LBDDS was adversely 
affected. Precipitation of celecoxib was observed within 14 days (Table 5), producing fine 
needle crystals, in seven of the eight tested systems as indicated by PLM and XRD analyses. 
The aDS appeared to have a substantial effect on the physical stability of sLBDDS. The 
LCM+S system was the only system where physical stability extended beyond 28 days, which 
most likely reflects that this system had the lowest aDS of 1.35, whereby for the sLBDDS 
with an aDS of  ≥1.57, drug precipitation was observed. The mixed MC sLBDDS MCM+S, 
MCM+MCT+S, MCM+LCT+S were the least stable systems, relative to comparable LC 
sLBDDS. The precipitate from all sLBDDS was analysed by PLM and XRD and was 
confirmed to be crystalline and having similar shape and structure as the starting drug 
material (XRD diffractograms shown in Supporting information, Figure S 5.       
3.5.2. Cinnarizine sLBDDS 
For all cinnarizine sLBDDS precipitation was observed within 28 days (Table 6 and 
Supporting information, Figure S 6 and Figure S 7). While there was a trend towards poorer 
stability for sLBDDS prepared at 60°C, compared to sLBDDS prepared at 37°C, even at 
relatively low aDS (e.g. 1.1 for MCM+S) supersaturation was only maintained for up to 7 
days on storage. The excipient type did not seem to affect the physical stability greatly, but 
rather an inherent poor stability of cinnarizine was observed in all sLBDDS independent of 
lipid composition. 
3.5.3. JNJ-2A sLBDDS 
For JNJ-2A, the aDS at both 37°C and 60°C were generally lower, compared to both 
celecoxib and cinnarizine, indicating that the propensity to generate supersaturation for JNJ-
2A in LBDDS was lower. In fact, at 37°C, effectively no supersaturation was achieved (i.e. 












equilibrium solubility observed at 37°C (Table 4). At the higher processing temperature of 
60°C, supersaturation was generated in four of the tested LBDDS (aDS 1.12-1.47), and 
supersaturation was maintained for all of these systems during the 28 days period, with no 
evidence of drug precipitation (Table 7). 
4. Discussion 
In the field of supersaturated LBDDS, a gap was identified in the pre-formulation of such 
drug delivery systems and thus there was a need to systematically assess the influence of 
excipient type, formulation complexity and drug physico-chemical properties on the ability to 
design sLBDDS. The current study has shown that lipid composition highly influences the 
dose loading ability and that the degree of supersaturation in sLBDDS was mainly drug-
dependent. The apparent degree of supersaturation was a major factor impacting ability to 
maintain drug supersaturation upon storage. 
A plot of logarithmic drug solubility versus temperature was useful for assessing the 
impact of temperature on drug solubility in lipids. The increases in solubility did not deviate 
greatly from linearity, indicating that the increased dose loadings in LBDDS at elevated 
temperature could be predicted based on extrapolation. While all three drugs displayed 
increased drug concentrations at higher temperature, the lines connecting the different data 
points for a lipid system were superimposable between the various LBDDS, indicative of a 
minor impact of composition type on propensity for supersaturation. In contrast, the lines of 
the thermal induced solubility increases were highly drug-dependent. Specifically, celecoxib 
and cinnarizine showed steep increases in solubility with temperature (i.e. up to 172.8% and 
196.0% more drug solubilized relative to solubility at ambient temperature), which may be a 
consequence of the smaller size and more rigid/compact shape of the molecules. In contrast, 
JNJ-2A, which displayed the highest equilibrium solubility in lipids at ambient temperature 












donors, exhibited a relatively low overall thermal induced solubility increase in LBDDS (up 
to 87.7% more drug solubilized compared to ambient temperature drug solubility). To the best 
of our knowledge this was the first time that apparent supersaturation in LBDDS was studied 
more systematically for different temperatures and compositions. This approach was therefore 
a useful systematic approach in early development of supersaturated LBDDS to aid the 
identification of an optimised high dose load sLBDDS. 
 In this work, the apparent degree of supersaturation (aDS) was used as a measurement 
of drug supersaturation in different LBDDS and thus an indicator of the likelihood of 
designing sLBDDS -. Using celecoxib, cinnarazine and JNJ—2A as model drugs, 
supersaturated LBDDS were successfully prepared (aDS ≥ 1.1) after a mild heating at 37°C of 
seven LBDDS containing celecoxib (aDS = 0.92 – 1.36) and seven containing cinnarizine 
(aDS = 1.02 – 1.38). In the case of JNJ-2A it was not possible to generate sLBDDS at 37°C 
(aDS = 0.79 – 1.04). At a higher temperature of 60°C, sLBDDS were successfully prepared 
for all tested LBDDS containing celecoxib (aDS = 1.35 – 2.97) and cinnarizine (aDS = 1.33 – 
3.33). Supersaturation of JNJ-2A using 60°C heating (aDS > 1.1) was only feasible in four 
LBDDS: LCM (aDS = 1.38), LCM+S (aDS = 1.12), MCM+S (aDS = 1.12) and 
MCM+MCT+S (aDS = 1.47). The relatively high solubility values obtained for JNJ-2A in 
LBDDS at ambient temperature and the lack of solubility increase with temperature elevation 
resulted in a lower degree of supersaturation obtainable using the suggested heating-cooling 
methodology. The effect may be explained by the solid-state characteristics of this drug (i.e. 
low crystallinity), which resulted in high solvation in lipid vehicles at ambient temperature, 
leaving little room for a solubilization gain from temperature elevation. A tabulated 
representation of the composition influence on the aDS after heating at 60°C and cooling at 
ambient temperature is illustrated in Table 8 as a summary for the keen reader. 
The ability to maintain supersaturation upon storage was assessed in this study by 












period in all cinnarizine sLBDDS (aDS of 1.02-– 3.33) and celecoxib sLBDDS with aDS 
>1.35, whereas no visible precipitate was observed for JNJ-2A in any of the sLBDDS (aDS = 
0.88 – 1.47). The lipid composition type had a relatively minor impact on the risk of 
precipitation during storage; however, it appeared that the aDS value was a major determinant 
of the risk of drug precipitation from sLBDDS containing celecoxib and cinnarizine. A higher 
aDS, such as achieved upon heating drug and LBDDS mixtures to 60°C, tended to result in 
faster precipitation compared to LBDDS heated at 37°C for celecoxib and cinnarizine. 
Nonetheless, the risk of precipitation was also highly dependent on the drug, whereby in the 
case of celecoxib and JNJ-2A, sLBDDS with aDS up to 1.35 and 1.47 respectively, were 
stable over the 28 days study period. In contrast, for cinnarizine, precipitation was evident in 
all sLBDDS, even at relatively low aDS, which would indicate an intrinsically poor physical 
stability in sLBDDS. An inherently poor stability of cinnarizine in drug delivery systems 
containing lipids has been previously reported [16]. Poor physical stability of a liquid 
cinnarizine SNEDDS containing either MC or LC lipid excipients was reported by Shabba 
and co-workers [31]. Similarly, Siqueira and co-workers, reported poor physical stability and 
a tendency for precipitation of cinnarizine from supersaturated SNEDDS [16]. Considering all 
the above, it would appear that for certain PWSDs such as cinnarizine, caution is advised 
when such drugs have an inherently poor stability in lipid systems. Alternatively strategies to 
improve stability of the supersaturated formulations, such as solid-state formulations may be 
merited.  For example Schultz and co-workers have reported an aproach to overcome 
instablity of sLBDDS of ibuprofen, using silica-lipid hybrids, where nanopores of porous 
silica microparticles inhibit the precipitation of the IBU and produce a solid-state LBDDS 
[32]. A focused representation of the LBDDS composition on the physical stability of 
sLBDDS formulated at 60°C is depicted in Table 9 and shows a general positive influence of 
additional lipid excipients or surfactant to the LCM excipient and a negative influence of such 












This study was also designed to evaluate the influence of lipid composition type on 
drug solubility in LBDDS at different temperature and thus on the ability to design 
supersaturated LBDDS using the heating-cooling approach.  Drug solubility was higher in 
MC versus LC lipids at all tested temperatures. This was particularly the case for celecoxib 
and JNJ-2A, and to a lesser extent cinnarizine. Similarly, a greater effect on the solubility gain 
by incorporation of a hydrophilic surfactant was observed for celecoxib and JNJ-2A and had a 
limited influence on cinnarizine solubility. Lipid composition type influenced the equilibrium 
solubility, which in turn dictates drug loading in sLBDDS. In this study, it appeared that the 
supersaturation propensity for celecoxib and cinnarizine was higher in single-component 
systems (LCM, MCM) compared to the more complex LBDDS. Additionally, for both model 
drugs higher aDS were determined in the LCM system compared to MCM. Across the 
LBDDS with more than one component, slightly higher aDS were seen for celecoxib in MC 
sLBDDS and for cinnarizine in LC sLBDDS. This observation could be potentially explained 
by the logP values of the two drugs, where a lower value (i.e. 4.3) for celecoxib would 
indicate preference for more polar mixtures of lipid excipients (i.e. medium chain [8,33,34] 
and a higher value (i.e. 5.7) would suggest an affinity for more lipophilic mixtures of lipid 
excipients (i.e. long chain). No clear LC versus MC influence on supersaturation propensity 
was seen for JNJ-2A, however, results indicate that simple LBDDS (i.e. LCM, LCM+S, 
MCM+S), as in the case of the other two model drugs, had the ability to maintain drug 
supersaturation.   
This work targeted a better understanding of the relevance of physico-chemical 
properties on the supersaturation propensity in LBDDS. The rank order of the supersaturation 
propensity of the three drugs was celecoxib ≥ cinnarizine > JNJ-2A based on the increases in 
drug solubility with elevation of temperature, i.e. 1.8 – 2.7-fold for celecoxib, 1.6 – 3.0-fold 
for cinnarizine and 1.0 – 1.9-fold for JNJ-2A. The more rigid structures with lower molecular 











2A may explain this ranking order and the clear influence of elevated temperature on drug 
solubility. Generally, the PWSDs investigated in super-SNEDDS were either weak bases 
(halofantrine [14,15], cinnarizine [16]) or neutral drugs (simvastatin [13], fenofibrate [24]). 
The present study was to our knowledge the first one to incorporate a weak acid (celecoxib) in 
comparison to a weak base (cinnarizine) and a neutral drug (JNJ-2A) in evalution of drug 
supersaturation in LBDDS. Interestingly, celecoxib showed the best potential for thermally-
induced drug supersaturation in the tested LBDDS with suitable physical stability for 
preclinical trials. However, due to the rather limited number of drugs overall, it is difficult to 
extract general conclusions at this point based on the acid-base-neutral characteristics. The 
thermal characteristics, such as Tm/Tg ratio, correlated well with previously published 
observations that a high Tm/Tg ratio implies a higher crystallization tendency and a more 
unstable amorphous form, which resulted in the re-crystallization and precipitation of 
celecoxib and cinnarizine from sLBDDS. In a study by Baird and co-workers, a classification 
systems was suggested based on the crystallization tendency and GFA of 51 organic 
molecules using the heat-cool-heat mode of the DSC [28]. A similar protocol was used in this 
study to potentially explain the supersaturation propensity of the three model drugs in 
LBDDS. The present work was in line with the proposed crystallisation classification for 
cinnarizine as a drug which re-crystallizes above Tg upon re-heating (i.e. class II drug). 
Celecoxib displays crystallization upon cooling at a cooling rate of 10°C/min and thus can be 
considered a class I drug which is different from the classification made by Baird et al. 
Nevertheless, in the Baird et al. study re-crystallization of celecoxib upon cooling at a slow 
rate of 1°C/min was reported, which may indicate that the crystallization behaviour of 
celecoxib could be reflective of batch to batch variability for which class II drugs are more 
susceptible [28]. JNJ-2A does not crystallize upon cooling or reheating, and therefore is 
believed to remain in an amorphous form (i.e. a class III drug) with a lower tendency to re-












entropy of fusion. The observable crystallization tendency of celecoxib and cinnarizine 
correlates well with the faster time to precipitate from sLBDDS upon storage. GFA of  
PWSDs was correlated previously with the supersaturation propensity of drugs upon aqueous 
dispersion in a study by Blaabjerg et al. [27]. In the present study, the poor glass forming 
drugs (i.e. celecoxib and cinnarizine) generated high degrees of supersaturation on heating in 
all tested LBDDS with the drawback of drug precipitation upon storage, while much lower 
aDS were determined for a drug with high glass forming ability (i.e. JNJ-2A), yet without any 
drug precipitation. Therefore, the crystallization behaviour of drugs may potentially explain 
the time to precipitate upon storage from sLBDDS, while properties such as high glass 
forming ability (i.e. class III drugs) and strong drug-lipid interactions and their influence on 
the drug solubility in lipids may be relevant factors for designing precipitation risk-free 












This work provided a pre-formulation screening  for assessment of composition influence and 
of drug physico-chemical properties on the design and short-term stability of sLBDDS.  - The 
study demonstrated that drug loadings of between 130-150% could be successfully achieved 
in sLBDDS with associated stability in excess of 28 days. Even higher dose loadings in 
sLBDDS were achieved (i.e. up to 300% relative to LBDDS,) albeit the risk of precipitation 
on storage increased at higher aDS.  The study therefore supports the utility of sLBDDS in 
bio-enabling strategy for PWSD candidates in preclinical toxicology studies where high doses 
are required and short-term formulation stability i.e. 1-28 days is considered sufficient. The 
solid-state properties of the drugs were useful in predicting the risk of precipitation on storage 
from sLBDDS, while properties such as high glass forming ability (i.e. class III drugs) and 
good lipid solubility were considered favourable for formulation as sLBDDS. Further studies 
are required involving a wider range of drugs to allow a more thorough understanding of the 
impact of drug properties on design and performance of sLBDDS. Additionally, in vitro 
dissolution and in vivo evaluations may be useful for identifying the performance of such 
delivery systems. 
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Table 1. Composition of two groups of lipid-based drug delivery systems containing single 
lipid components (LCM, MCM) and mixtures of 2-3 lipid excipients (LCM+S, MCM+S, 
LCM+LCT+S, MCM+LCT+S, LCM+MCT+S, MCM+LCT+S) 
Group Abbreviation Excipients Composition (w/w, %) 
LCM-
based 
LCM Maisine CC 100 
LCM+S Maisine CC + Labrasol 80 + 20 
LCM+LCT+S Maisine CC + Sesame oil + Labrasol 40 + 40 + 20 
LCM+MCT+S Maisine CC + Labrafac + Labrasol 40 + 40 + 20 
MCM-
based 
MCM Capmul MCM 100 
MCM+S Capmul MCM + Labrasol 80 + 20 
MCM+MCT+S Capmul MCM + Labrafac + Labrasol 40 + 40 + 20 
MCM+LCT+S Capmul MCM + Sesame oil + Labrasol 40 + 40 + 20 
Table 2. Physico-chemical properties of poorly water-soluble drugs 
Drug Celecoxib Cinnarizine JNJ-2A
c
 
BCS class II II II 




 < 0.2 
MW (g/mol) 381.4 368.5 498.9 
Melting point (°C) 163 121 142 









 2.02 ;12.12 
Molecular weight (MW), melting point and logP for celecoxib, cinnarizine from Baird et al.[28]  
a https://www.drugbank.ca/drugs/DB00568 
b pKa values for cinnarizine from Larsen et al.[35]  
c Physico-chemical properties of JNJ-2A are results of in-house analysis  
Table 3. Enthalpy of fusion (ΔHfus), melting peak temperature (Tm), entropy of fusion (ΔSfus), 
Tm/Tg ratio, crystallization peak temperature during cooling (Tcryst,cool), onset and midpoint 
glass transition temperatures (Tg,onset, Tg,mid), and crystallization peak upon heating (Tcryst,heat) 
























Celecoxib 34.1 162.4 7.8 1.32 138.0 N/A N/A 160.5 
Cinnarizi
ne 
37.5 121.4 9.5 1.41 N/A 7.2 8.5 82.5 
JNJ-2A 22.9 140.2 5.5 1.14 N/A 89.3 91.2 N/A 
 
*Entropy of fusion was calculated as the ratio of enthalpy of fusion (kJ/mol) and melting peak temperature (Kelvin), where 
Tm(K) is 435.55K (celecoxib), 394.55K (cinnarizine) and 413.35K (JNJ-2A) 
^Mid Tg (Kelvin) used for calculation of Tm/Tg was 331.15 K (celecoxib) according to Baird et al. [28] and 280.35 K 













Table 4. Solubility values (mean ± SD) at ambient temperature (AT), 37°C and 60°C for 
celecoxib, cinnarizine and JNJ-2A in eight LBDDS  
n.d = not determined due to clear phase separation 
 
 
Table 5. Apparent degree of supersaturation and physical stability evaluation for investigated 
supersaturated celecoxib lipid-based drug delivery systems at 25°C/65%RH for 28 days 
 
Celecoxib 






LCM 1.14 >28 2.97 <1 
LCM+S 1.13 >28 1.35 >28 
LCM+LCT+S 1.36 >28 1.73 7 - 14 
LCM+MCT+S 1.13 >28 1.57 4 - 7 
MCM 1.31 >28 2.04 1 - 4 
MCM+S 0.92 >28 1.72 <1 
MCM+MCT+S 1.23 >28 1.81 <1 
MCM+LCT+S 1.33 >28 2.23 <1 
  
 Celecoxib Cinnarizine JNJ-2A 





































LCM + LCT 












n.d. n.d. n.d. 




























283±16 348±12 293±28 




















































Table 6. Apparent degree of supersaturation and physical stability evaluation for investigated 
supersaturated cinnarizine lipid-based drug delivery systems at 25°C/65%RH for 28 days 
 
Cinnarizine 






LCM 1.23 14 - 28 3.33 <1 
LCM+S 1.27 14 - 28 2.55 1 - 4 
LCM+LCT+S 1.19 14 - 28 1.33 1 - 4 
LCM+MCT+S 1.02 7 - 14 2.63 7 - 14 
MCM 1.24  1- 4 2.78 7 - 14 
MCM+S 1.10 7 - 14 2.16 4 - 7 
MCM+MCT+S 1.13 7 - 14 2.09 <1 
MCM+LCT+S 1.38 7 - 14 2.42 4 - 7 
 
Table 7. Apparent supersaturation degrees and physical stability evaluation for investigated 
supersaturated JNJ-2A lipid-based drug delivery systems at 25°C/65%RH for 28 days 
 
JNJ-2A 






LCM 0.94 >28 1.38 >28 
LCM+S 0.79 >28 1.12 >28 
LCM+LCT+S n.d. unstable n.d. unstable 
LCM+MCT+S n.d. unstable n.d. unstable 
MCM 0.92 >28 0.92 >28  
MCM+S 0.87 >28 1.12 >28 
MCM+MCT+S 1.04 >28 1.47 >28 














Table 8. Schematic representation of findings on the influence of LBDDS composition on the 




















Celecoxib LCM>MCM decrease decrease decrease decrease decrease increase 
Cinnarizine LCM>MCM decrease decrease decrease decrease decrease decrease 
JNJ-2A LCM>MCM decrease n.a. n.a. increase increase n.a. 
 
Table 9. Schematic representation of findings on the influence of LBDDS composition on the 





























Celecoxib MCM>LCM increase increase increase decrease decrease increase 
Cinnarizin
e 
MCM>LCM increase increase increase decrease decrease decrease 





















Figure 1. Solubility (mg/mL) of celecoxib (black bars), cinnarizine (dark grey bars) and JNJ-





Figure 2.  Plots of logS (log of drug solubility at ambient temperature, 37°C and 60°C) of 
drugs used in the study (celecoxib, cinnarizine and JNJ-2A) as a function of temperature. 
Lines are depicted as guides to the eye. 
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